{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:04:34Z","timestamp":1790647474762,"version":"4.1.0"},"reference-count":191,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Non-Hodgkin lymphoma (NHL) is the third most common malignancy diagnosed in children. The vast majority of paediatric NHL are either Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma (LL). Multi-agent chemotherapy is used to treat all of these types of NHL, and survival is over 90% but the chemotherapy regimens are intensive, and outcomes are generally poor if relapse occurs. Therefore, targeted therapies are of interest as potential solutions to these problems. However, the major problem with all targeted agents is the development of resistance. Mechanisms of resistance are not well understood, but increased knowledge will facilitate optimal management strategies through improving our understanding of when to select each targeted agent, and when a combinatorial approach may be helpful. This review summarises currently available knowledge regarding resistance to targeted therapies used in paediatric anaplastic lymphoma kinase (ALK)-positive ALCL. Specifically, we outline where gaps in knowledge exist, and further investigation is required in order to find a solution to the clinical problem of drug resistance in ALCL.<\/jats:p>","DOI":"10.3390\/cancers13236003","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T22:50:45Z","timestamp":1638226245000},"page":"6003","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL"],"prefix":"10.3390","volume":"13","author":[{"given":"Lucy","family":"Hare","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK"},{"name":"Department of Paediatric Oncology and Haematology, Addenbrooke\u2019s Hospital, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-9972","authenticated-orcid":false,"given":"G. A. Amos","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology and Haematology, Addenbrooke\u2019s Hospital, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-4507","authenticated-orcid":false,"given":"Suzanne D.","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK"},{"name":"CEITEC, Masaryk University, 62500 Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Prokoph, N., Larose, H., Lim, M.S., Burke, G.A.A., and Turner, S.D. (2018). Treatment options for paediatric anaplastic large cell lymphoma (ALCL): Current standard and beyond. Cancers, 10.","DOI":"10.3390\/cancers10040099"},{"key":"ref_2","unstructured":"Abla, O., Alexander, S., Attarbaschi, A., Batchelor, T.T., Beishuizen, A., Bond, J., Borkhardt, A., Brugieres, L., Burke, A., and Burkhardt, B. (2019). Non-Hodgkin\u2019s Lymphoma in Childhood and Adolescence, Springer International Publishing. [1st ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1128\/MCB.17.4.2312","article-title":"Role of the nucleophosmin (NPM) portion of the non-Hodgkin\u2019s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis","volume":"17","author":"Bischof","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7750","DOI":"10.1038\/sj.onc.1207048","article-title":"Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase","volume":"22","author":"Turner","year":"2003","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10087","DOI":"10.1038\/ncomms10087","article-title":"Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress","volume":"7","author":"Malcolm","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2002-05-1343","article-title":"NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors","volume":"101","author":"Chiarle","year":"2003","journal-title":"Blood"},{"key":"ref_9","first-page":"3275","article-title":"CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy","volume":"26","author":"Turner","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2016-05-717793","article-title":"Nucleophosmin-anaplastic lymphoma kinase: The ultimate oncogene and therapeutic target","volume":"129","author":"Werner","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cellsig.2006.09.007","article-title":"The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms","volume":"19","author":"Turner","year":"2007","journal-title":"Cell. Signal."},{"key":"ref_12","first-page":"2194","article-title":"Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagenesis","volume":"61","author":"Slupianek","year":"2001","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4049\/jimmunol.168.1.466","article-title":"Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T\/null-cell lymphoma","volume":"168","author":"Zhang","year":"2002","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1128\/MCB.18.12.6951","article-title":"Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity","volume":"18","author":"Bai","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ducray, S.P., Natarajan, K., Garland, G.D., Turner, S.D., and Egger, G. (2019). The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis. Cancers, 11.","DOI":"10.3390\/cancers11081074"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sharma, G.G., Mota, I., Mologni, L., Patrucco, E., Gambacorti-Passerini, C., and Chiarle, R. (2018). Tumor resistance against ALK targeted therapy\u2014Where it comes from and where it goes. Cancers, 10.","DOI":"10.3390\/cancers10030062"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Trigg, R.M., and Turner, S.D. (2018). ALK in neuroblastoma: Biological and therapeutic implications. Cancers, 10.","DOI":"10.3390\/cancers10040113"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/leu.2011.209","article-title":"Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns","volume":"26","author":"Laurent","year":"2012","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bjh.13958","article-title":"Anaplastic large cell lymphoma in paediatric and young adult patients","volume":"173","author":"Turner","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2017.177972","article-title":"Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"103","author":"Ruf","year":"2018","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2004-03-1037","article-title":"Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling","volume":"104","author":"Bonzheim","year":"2004","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"160232","DOI":"10.1098\/rsob.160232","article-title":"Challenging perspectives on the cellular origins of lymphoma","volume":"6","author":"Malcolm","year":"2016","journal-title":"Open Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41375-018-0045-9","article-title":"The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17\/ILC3 skewing of anaplastic large cell lymphoma","volume":"32","author":"Schleussner","year":"2018","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/onc.2014.112","article-title":"Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin","volume":"34","author":"Moti","year":"2015","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1172\/JCI134990","article-title":"ALK-transformed mature T lymphocytes restore early thymus progenitor features","volume":"130","author":"Congras","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9964","DOI":"10.1073\/pnas.0603507103","article-title":"Nucleophosmin\/anaplastic lymphoma kinase (NPM\/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3","volume":"103","author":"Kasprzycka","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.ajpath.2013.08.030","article-title":"The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes","volume":"183","author":"Zhang","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.4049\/jimmunol.1300744","article-title":"Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM\/ALK recapitulates IL-2\u2013induced cell signaling and gene expression reprogramming","volume":"191","author":"Marzec","year":"2013","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL group","volume":"27","author":"Rosolen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.leu.2403888","article-title":"Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma","volume":"19","author":"Mussolin","year":"2005","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1002\/pbc.24591","article-title":"Central nervous system involvement in anaplastic large cell lymphoma in childhood: Results from a multicentre European and Japanese study","volume":"60","author":"Williams","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mussolin, L., Le Deley, M.C., Carraro, E., Damm-Welk, C., Attarbaschi, A., Williams, D., Burke, A., Horibe, K., Nakazawa, A., and Wrobel, G. (2020). Prognostic factors in childhood anaplastic large cell lymphoma: Long term results of the international ALCL99 trial. Cancers, 12.","DOI":"10.3390\/cancers12102747"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/pbc.22940","article-title":"Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: Report of the ALCL99 randomised trial","volume":"56","author":"Wrobel","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_35","first-page":"35","article-title":"Risk-adapted therapy for patients with relapsed or refractory ALCL\u2014Final report of the prospective ALCL-relapse trial of the EICNHL","volume":"171","author":"Ruf","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_36","unstructured":"EMC (2021, May 15). Vinblastine Sulphate 1 mg\/mL Injection. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/1422\/smpc#gref."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1200\/JCO.2008.20.1764","article-title":"Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology","volume":"27","author":"Brugieres","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","article-title":"Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized ALCL99-vinblastine trial","volume":"28","author":"Rosolen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/pbc.25187","article-title":"Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children\u2019s oncology group","volume":"61","author":"Alexander","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-018-0209-3","article-title":"Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1","volume":"8","author":"Li","year":"2018","journal-title":"Cell Biosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0022-5347(17)39586-1","article-title":"Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma","volume":"144","author":"Mickisch","year":"1990","journal-title":"J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0165-4608(01)00519-2","article-title":"Cytogenetic characterization of chromosomal rearrangement in a human vinblastine-resistant CEM cell line: Use of comparative genomic hybridization and fluorescence in situ hybridization","volume":"132","author":"Struski","year":"2002","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2141.1989.tb07649.x","article-title":"Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia","volume":"72","author":"Holmes","year":"1989","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1016\/0006-2952(86)90710-0","article-title":"Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells","volume":"35","author":"Zamora","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/bjc.1998.493","article-title":"Reversal of vinblastine transport by chlorpromazine in membrane vesicles from multidrug-resistant human CCRF-CEM leukaemia cells","volume":"78","author":"Syed","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41598-018-19325-x","article-title":"Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells","volume":"8","author":"Nanayakkara","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bbrc.2005.07.194","article-title":"Role of c-Jun in cellular sensitivity to the microtubule inhibitor vinblastine","volume":"335","author":"Obey","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_49","first-page":"E81","article-title":"Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization","volume":"91","author":"Dumontet","year":"2004","journal-title":"Bull. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-016-3220-6","article-title":"First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: A report on ADVL0912 from the Children\u2019s Oncology Group Phase 1\/Pilot Consortium","volume":"79","author":"Balis","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/sj.onc.1201062","article-title":"ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin\u2019s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)","volume":"14","author":"Morris","year":"1997","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.cell.2020.04.034","article-title":"Identification of ALK in Thinness","volume":"181","author":"Orthofer","year":"2020","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/sj.npp.1301446","article-title":"Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications","volume":"33","author":"Bilsland","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_55","unstructured":"FDA (2021, May 15). FDA Approves Crizotinib for Children and Young Adults with Relapsed or Refractory, Systemic Anaplastic Large Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A Children\u2019s Oncology Group study","volume":"35","author":"Voss","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_57","first-page":"2831","article-title":"Crizotinib in advanced ALK+ anaplastic large cell lymphoma in children and adults: Results of the Acs\u00a9 phase II trial","volume":"130","author":"Houot","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00280-020-04171-4","article-title":"Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): A Children\u2019s Oncology Group phase 1 consortium study (ADVL1212)","volume":"86","author":"Greengard","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_60","unstructured":"EU Clinical Trials Register (2021, May 31). A phase 1B of Crizotinib Either in Combination or as Single Agent in Pediatric Patients with ALK, ROS1 or MET Positive Malignancies. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005437-53\/NL."},{"key":"ref_61","unstructured":"ClinicalTrials.gov (2021, May 31). Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01979536."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2019.11.004","article-title":"Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial","volume":"15","author":"Huber","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: Results of COG trial ANHL12P1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41375-021-01191-8","article-title":"Targeted based therapy in nodal T-cell lymphomas","volume":"35","author":"Chihara","year":"2021","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Leonard","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma: A multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood.2021011572","article-title":"Brentuximab vedotin: Frontline help in ALCL","volume":"137","author":"Burke","year":"2021","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"eaay1863","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7326\/L16-0037","article-title":"Nivolumab for refractory anaplastic large cell lymphoma: A case report","volume":"165","author":"Hebart","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e26902","DOI":"10.1002\/pbc.26902","article-title":"Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma","volume":"65","author":"Rigaud","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1511045","article-title":"Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib","volume":"374","author":"Mussolin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00432-014-1589-3","article-title":"Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma","volume":"140","author":"Zdzalik","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Andraos, E., Dignac, J., and Meggetto, F. (2021). NPM-ALK: A driver of lymphoma pathogenesis and a therapeutic target. Cancers, 13.","DOI":"10.3390\/cancers13010144"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cllc.2019.02.013","article-title":"Relevance of detection of mechanisms of resistance to ALK inhibitors in ALK-rearranged NSCLC in routine practice","volume":"20","author":"Jamme","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1541-7786.MCR-14-0157","article-title":"Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma","volume":"13","author":"Ceccon","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1158\/0008-5472.CAN-14-3437","article-title":"Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK+ tumors","volume":"75","author":"Amin","year":"2015","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1038\/onc.2015.456","article-title":"Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency","volume":"35","author":"Ceccon","year":"2016","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/s41388-019-1136-4","article-title":"The mechanism of cancer drug addiction in ALK-positive T-cell lymphoma","volume":"39","author":"Rajan","year":"2020","journal-title":"Oncogene"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.2147\/CMAR.S260274","article-title":"Optimal care for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer: A review on the role and utility of ALK inhibitors","volume":"12","author":"Singh","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bui, K.T., Cooper, W.A., Kao, S., and Boyer, M. (2018). Targeted molecular treatments in non-small cell lung cancer: A clinical guide for oncologists. J. Clin. Med., 7.","DOI":"10.3390\/jcm7080192"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: Precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2019.01.019","article-title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance","volume":"41","author":"Okada","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/cas.14314","article-title":"Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms","volume":"111","author":"Yanagitani","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.413","article-title":"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK","volume":"4","author":"Fontana","year":"2015","journal-title":"Cancer Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s10822-020-00355-5","article-title":"Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics","volume":"34","author":"Chen","year":"2020","journal-title":"J. Comput. Aided. Mol. Des."},{"key":"ref_96","first-page":"160","article-title":"A Computational approach for prioritizing selection of therapies targeting drug resistant variation in anaplastic lymphoma kinase","volume":"2017","author":"McCoy","year":"2018","journal-title":"AMIA Summits Transl. Sci. Proc."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-11-1648","article-title":"ALK mutations conferring differential resistance to structurally diverse ALK inhibitors","volume":"17","author":"Heuckmann","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.06.043","article-title":"Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: A multicenter study using targeted next-generation sequencing","volume":"156","author":"Lin","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","article-title":"The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers","volume":"70","author":"Sasaki","year":"2010","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"a006064","DOI":"10.1101\/mcs.a006064","article-title":"Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma","volume":"7","author":"Liu","year":"2021","journal-title":"Mol. Case Stud."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2018.07.004","article-title":"Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient","volume":"123","author":"Ai","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Gristina, V., La Mantia, M., Iacono, F., Galvano, A., Russo, A., and Bazan, V. (2020). The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120474"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1541-7786.MCR-12-0569","article-title":"Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors","volume":"11","author":"Ceccon","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"ref_105","first-page":"djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Farina","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtho.2018.06.020","article-title":"Activity of brigatinib in the setting of alectinib resistance mediated by ALK I1171S in ALK-rearranged lung cancer","volume":"14","author":"Sehgal","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"23715","DOI":"10.18632\/oncotarget.8173","article-title":"TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors","volume":"7","author":"Amin","year":"2016","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lungcan.2017.05.018","article-title":"Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib","volume":"110","author":"Zhu","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_110","first-page":"111","article-title":"Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation","volume":"9","author":"Zhu","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cancergen.2021.03.006","article-title":"Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non\u2013small-cell lung cancer","volume":"256","author":"Suryavanshi","year":"2021","journal-title":"Cancer Genet."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Ferrara, M.G., Di Noia, V., D\u2019Argento, E., Vita, E., Damiano, P., Cannella, A., Ribelli, M., Pilotto, S., Milella, M., and Tortora, G. (2020). Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives. Cancers, 12.","DOI":"10.3390\/cancers12051196"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2015.11.023","article-title":"A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib","volume":"92","author":"Kodityal","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/JTO.0000000000000509","article-title":"Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non-small-cell lung cancer exhibiting resistance to ceritinib","volume":"10","author":"Toyokawa","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_115","first-page":"376","article-title":"Ceritinib as a promising therapy for ALK related diseases","volume":"3","author":"Ceccon","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/1759-7714.13299","article-title":"Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer","volume":"11","author":"Takahashi","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/15384047.2018.1433496","article-title":"Capture-based ultra-deep sequencing in plasma ctDNA reveals the resistance mechanism of ALK inhibitors in a patient with advanced ALK-positive NSCLC","volume":"19","author":"Guo","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2014.05.020","article-title":"Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance","volume":"351","author":"Kodama","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2147\/OTT.S293901","article-title":"Identification of novel Alectinib-resistant ALK mutation G1202K with sensitization to lorlatinib: A case report and in silico structural modelling","volume":"14","author":"Yang","year":"2021","journal-title":"Onco Targets Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2020.1836947","article-title":"The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: A case report","volume":"22","author":"Meng","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.jtho.2019.06.028","article-title":"A compound L1196M\/G1202R ALK mutation in a patient with ALK-positive lung cancer with acquired resistance to brigatinib also confers primary resistance to lorlatinib","volume":"14","author":"Sharma","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.18632\/oncotarget.3122","article-title":"NPM\/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922","volume":"6","author":"Mologni","year":"2015","journal-title":"Oncotarget"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.1158\/0008-5472.CAN-18-1867","article-title":"Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer","volume":"78","author":"Redaelli","year":"2018","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.critrevonc.2019.03.013","article-title":"Current management of neuroblastoma and future direction","volume":"138","author":"Pastor","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-19-1104","article-title":"Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nm.3667","article-title":"Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer","volume":"20","author":"Lovly","year":"2014","journal-title":"Nat. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2007-11-125658","article-title":"IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells","volume":"114","author":"Shi","year":"2009","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Rossing, H.H., Grauslund, M., Urbanska, E.M., Melchior, L.C., Rask, C.K., Costa, J.C., Skov, B.G., S\u00f8rensen, J.B., and Santoni-Rugiu, E. (2013). Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: A case report. BMC Res. Notes, 6.","DOI":"10.1186\/1756-0500-6-489"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/1878-0261.13033","article-title":"NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: A step toward personalized NSCLC treatment","volume":"15","author":"Ivanchuk","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1541-7786.MCR-16-0211","article-title":"Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer","volume":"15","author":"Miyawaki","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.18632\/oncotarget.2055","article-title":"Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells","volume":"5","author":"Tanimoto","year":"2014","journal-title":"Oncotarget"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"787","DOI":"10.21037\/tlcr.2020.04.03","article-title":"Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report","volume":"9","author":"Minari","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neo.2016.02.001","article-title":"Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small cell lung cancer cells","volume":"18","author":"Dong","year":"2016","journal-title":"Neoplasia"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3892\/ijo.2014.2797","article-title":"Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer","volume":"46","author":"Kogita","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1541-7786.MCR-18-0325","article-title":"Alectinib resistance in ALK-rearranged lung cancer by dual salvage signaling in a clinically paired resistance model","volume":"17","author":"Tsuji","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41419-020-2307-5","article-title":"Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2020.05.018","article-title":"BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer","volume":"146","author":"Shi","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"E6030","DOI":"10.1073\/pnas.1717782115","article-title":"YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics","volume":"115","author":"Fan","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","first-page":"1657","article-title":"IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma","volume":"136","author":"Prokoph","year":"2020","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Karaca-Atabay, E., Mecca, C., Wang, Q., Ambrogio, C., Mota, I., Prokoph, N., Mura, G., Martinengo, C., Patrucco, E., and Leonardi, G. (2021). Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood, in press.","DOI":"10.1182\/blood.2020008136"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nm.3930","article-title":"RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer","volume":"21","author":"Hrustanovic","year":"2015","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2016.01.002","article-title":"K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature","volume":"93","author":"Mengoli","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/onc.2015.434","article-title":"ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT","volume":"35","author":"Debruyne","year":"2016","journal-title":"Oncogene"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3324\/haematol.2019.238766","article-title":"Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target","volume":"106","author":"Larose","year":"2021","journal-title":"Haematologica"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1038\/s41467-019-13315-x","article-title":"The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status","volume":"10","author":"Trigg","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3892\/ijo.2014.2574","article-title":"Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition","volume":"45","author":"Kogita","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Urbanska, E.M., S\u00f8rensen, J.B., Melchior, L.C., Costa, J.C., and Santoni-Rugiu, E. (2020). Changing ALK-TKI-resistance mechanisms in rebiopsies of ALK-rearranged NSCLC: ALK- and BRAF-mutations followed by epithelial-mesenchymal transition. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082847"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jtho.2015.12.097","article-title":"A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib","volume":"11","author":"Cha","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jtho.2015.12.105","article-title":"Transformation to SCLC after treatment with the ALK inhibitor alectinib","volume":"11","author":"Fujita","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.10.012","article-title":"Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors","volume":"102","author":"Levacq","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2019.05.025","article-title":"Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib","volume":"134","author":"Coleman","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-019-1472-0","article-title":"BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells","volume":"572","author":"Debruyne","year":"2019","journal-title":"Nature"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccell.2019.09.009","article-title":"Thrown for a loop: Awakening BORIS to evade ALK inhibition therapy","volume":"36","author":"Berko","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.2147\/OTT.S258067","article-title":"Coexisting of COX7A2L-ALK, LINC01210-ALK, ATP13A4-ALK and acquired SLCO2A1-ALK in a lung adenocarcinoma with rearrangements loss during the treatment of crizotinib and ceritinib: A case report","volume":"13","author":"Cai","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"30149","DOI":"10.18632\/oncotarget.4999","article-title":"Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma","volume":"6","author":"Mitou","year":"2015","journal-title":"Oncotarget"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4161\/cbt.28162","article-title":"Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer","volume":"15","author":"Ji","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14728222.2020.1832465","article-title":"Targeting p53 in chronic lymphocytic leukemia","volume":"24","author":"Moia","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Moia, R., Patriarca, A., Schipani, M., Ferri, V., Favini, C., Sagiraju, S., Al Essa, W., and Gaidano, G. (2020). Precision medicine management of chronic lymphocytic leukemia. Cancers, 12.","DOI":"10.3390\/cancers12030642"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41420-018-0059-0","article-title":"The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas","volume":"4","author":"Miyazaki","year":"2018","journal-title":"Cell Death Discov."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.leu.2403840","article-title":"p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma","volume":"19","author":"Rassidakis","year":"2005","journal-title":"Leukemia"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1182\/blood-2008-06-160168","article-title":"NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner","volume":"113","author":"Cui","year":"2009","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/leu.2009.180","article-title":"The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53","volume":"23","author":"Drakos","year":"2009","journal-title":"Leukemia"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"72886","DOI":"10.18632\/oncotarget.12128","article-title":"Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma","volume":"7","author":"Redaelli","year":"2016","journal-title":"Oncotarget"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","article-title":"MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer","volume":"26","author":"Yoda","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hon.2560","article-title":"Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin","volume":"37","author":"Chihara","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_170","first-page":"634","article-title":"ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin","volume":"57","author":"Arai","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41416-020-0996-2","article-title":"CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma","volume":"123","author":"Fordham","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 Downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1158\/1078-0432.CCR-19-4137","article-title":"A20 and RBX1 regulate brentuximab vedotin sensitivity in hodgkin lymphoma models","volume":"26","author":"Wei","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","article-title":"Inhibition of MDR1 overcomes resistance to brentuximab vedotin in hodgkin lymphoma","volume":"26","author":"Chen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1634\/theoncologist.2017-0354","article-title":"Molecular biomarkers of primary and acquired resistance to T-cell-mediated immunotherapy in cancer: Landscape, clinical implications, and future directions","volume":"23","author":"Chae","year":"2018","journal-title":"Oncologist"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.drup.2021.100770","article-title":"Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function","volume":"57","author":"Gao","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Cretella, D., Digiacomo, G., Giovannetti, E., and Cavazzoni, A. (2019). PTEN alterations as a potential mechanism for tumor cell escape from PD-1\/PD-L1 inhibition. Cancers, 11.","DOI":"10.3390\/cancers11091318"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7150\/thno.38137","article-title":"Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21037\/tgh.2019.12.11","article-title":"Finding the hot spot: Identifying immune sensitive gastrointestinal tumors","volume":"5","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e001506","DOI":"10.1136\/jitc-2020-001506","article-title":"Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC","volume":"9","author":"Walsh","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1172\/JCI27745","article-title":"CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells","volume":"116","author":"Quezada","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","article-title":"Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy","volume":"88","author":"Restifo","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00262-020-02703-8","article-title":"Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)","volume":"70","author":"Kim","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"De Wispelaere, W., Annibali, D., Tuyaerts, S., Lambrechts, D., and Amant, F. (2021). Resistance to immune checkpoint blockade in uterine leiomyosarcoma: What can we learn from other cancer types?. Cancers, 13.","DOI":"10.3390\/cancers13092040"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e25773","DOI":"10.1097\/MD.0000000000025773","article-title":"Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report","volume":"100","author":"Yamaguchi","year":"2021","journal-title":"Medicine"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"S976","DOI":"10.1016\/j.jtho.2019.08.2141","article-title":"EP1.04-12 Response to combination of metformin and nivolumab in a NSCLC patient whose disease previously progressed on nivolumab","volume":"14","author":"Viveiros","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1034\/j.1399-0039.2003.00020.x","article-title":"Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: Beta2-microglobulin inactivation in MSI-positive tumors and LMP7\/TAP2 downregulation in MSI-negative tumors","volume":"61","author":"Cabrera","year":"2003","journal-title":"Tissue Antigens"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/6003\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:37:22Z","timestamp":1760168242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/6003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":191,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13236003"],"URL":"https:\/\/doi.org\/10.3390\/cancers13236003","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]}}}